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a b s t r a c t
Microscale thermophoresis (MST) allows for quantitative analysis of protein interactions in free solution
and with low sample consumption. The technique is based on thermophoresis, the directed motion of
molecules in temperature gradients. Thermophoresis is highly sensitive to all types of binding-induced
changes of molecular properties, be it in size, charge, hydration shell or conformation. In an all-optical
approach, an infrared laser is used for local heating, and molecule mobility in the temperature gradient
is analyzed via fluorescence. In standard MST one binding partner is fluorescently labeled. However, MST
can also be performed label-free by exploiting intrinsic protein UV-fluorescence.
Despite the high molecular weight ratio, the interaction of small molecules and peptides with proteins
is readily accessible by MST. Furthermore, MST assays are highly adaptable to fit to the diverse require-
ments of different biomolecules, such as membrane proteins to be stabilized in solution. The type of buf-
fer and additives can be chosen freely. Measuring is even possible in complex bioliquids like cell lysate
allowing close to in vivo conditions without sample purification. Binding modes that are quantifiable
via MST include dimerization, cooperativity and competition. Thus, its flexibility in assay design qualifies
MST for analysis of biomolecular interactions in complex experimental settings, which we herein demon-
strate by addressing typically challenging types of binding events from various fields of life science.
 2013 Elsevier Inc.
1. Introduction
1.1. The importance of biomolecular affinity quantification
Binding events involving proteins and other biomolecules play a
central role in all fields of life science, from molecular physiology
and pathology to diagnostics and pharmacology. Therefore, biomo-
lecular interaction analysis does not only give fundamental in-
sights into the molecular biology of the cell but also paves the
way towards improved disease treatment.
Cellular networks for signal transduction are mainly based on
the direct interaction of biomolecules. A typical example is the li-
gand binding-induced activation of cell membrane receptors. It
has recently been shown for the fibroblast growth factor receptor
(FGFR), that not only interaction with the ligand, but also with a
negative regulator is required for proper receptor function: binding
of growth factor receptor-bound protein 2 (Grb2) dimers inhibits
FGFR activation in absence of extracellular stimuli [1]. Pathological
alterations of these signal transduction networks have to be eluci-
dated to understand disease etiology. In infectious diseases, host
cell invasion is a critical step that involves specific protein–protein
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interactions. For instance, the malaria-causing microorganism Plas-
modium falciparum invades red blood cells through multiple recep-
tor-ligand interactions. One of the key steps requires injecting
parasite rhoptry neck proteins (RONs) [2]. RON2 then functions
as a receptor for apical membrane antigen 1 (AMA1) present on
the parasite’s surface. The interaction of RON2 and AMA1 is there-
fore of major interest as a potential drug target [3].
In these examples, qualitative binding studies alone would
hardly be sufficient. Instead, quantitative analysis not only allows
obtaining biologically relevant information but also evaluating it
in the context of the corresponding system. Microscale themopho-
resis (MST) quantifies biomolecular interactions based on the un-
ique physical principle of thermophoresis not utilized by any
other technique. As thermophoresis is influenced by binding-in-
duced changes of various molecular properties, MST distinguishes
itself from other biophysical techniques relying on measurable
changes in one single parameter. In addition, MST benefits from
very low sample consumption and short measurement times. Its
highly flexible assay design makes MST a widely applicable ap-
proach, even when the system of interest poses challenging condi-
tions. In this work, we place MST in the context of other well-
established biochemical and biophysical methods and illustrate
how it can be used to quantify interactions that are difficult to
quantify by other means. Measurements in cell lysate or in com-
plex buffers as are needed to stabilize GPCRs are shown. In addition
to small molecule interactions, homodimerization, binding events
comprising multiple constituents and cooperativity are discussed.
We furthermore give detailed information on the background of
MST and on its experimental implementation.
1.2. Tools for biomolecular binding analysis
The optimal approach to determine binding constants for a gi-
ven biological system can be selected by considering the specific
strengths and weaknesses of the currently available techniques.
Biochemical methods are straightforward to perform and compa-
rably low in cost and effort. They include electrophoretic mobility
shift assays (EMSA) for the study of protein-nucleic acid interac-
tions and antibody-based techniques such as enzyme linked
immunosorbent assays (ELISA) [4,5]. Despite their popularity and
application depth, classical biochemical methods are typically lim-
ited to semi quantitative interaction analysis [6].
A number of biophysical approaches, including isothermal titra-
tion calorimetry, dynamic light scattering, fluorescence polariza-
tion and surface plasmon resonance, do allow quantitative
binding studies. Isothermal titration calorimetry (ITC) has the
advantage of not requiring labeling or tethering. In this calorimet-
ric approach, the heat change upon binding is measured by titrat-
ing one binding partner into an adiabatic sample cell, which
contains a constant amount of the other binding partner. ITC gives
direct access to affinity, stoichiometry and thermodynamic param-
eters. However, sensitivity is low, requiring relatively high
amounts of sample to generate a sufficiently strong heat signal,
which can be difficult to achieve for biological samples. Binding
affinities from nM to sub-mM can be resolved with low throughput
[7–9]. Label-free, free solution binding analysis is also possible via
dynamic light scattering (DLS). DLS utilizes the autocorrelation of
time-dependent fluctuations in light scattered by biomolecules in
solution. The translational diffusion coefficient and thus the hydro-
dynamic radius (rH) of the biomolecules are inferred. A binding-in-
duced change in the average particle size can thus be detected. In
high-density plate formats, DLS allows for high-throughput mea-
surements of affinities in the low to high micromolar range. The
technique, however, relies on a significant difference in the rH of
the unbound partners relative to the complex and is thus limited
to binding partners that maximally differ by a factor of two in their
rH. It has to be taken into account that rH scales with the cube root
of the molecular weight. The sensitivity is thus lower for the bind-
ing of two larger proteins compared to the binding of two smaller
ones [10,11]. Another free solution method is fluorescence polari-
zation (FP; or fluorescence anisotropy). FP requires fluorescent
labeling of one of the binding partners, usually a small molecule li-
gand, which is then excited with polarized light. Fast rotation of
the small ligand causes the emitted light to be depolarized. Binding
of a larger protein leads to an increase in size and thus slower rota-
tion. As a result, the emitted light remains polarized to a greater
extent. FP allows for fully automated high-throughput analysis.
Applicability and sensitivity are limited by the relation of fluores-
cence lifetime of the dye, the size of the fluoroligand and the
molecular weight change upon binding. Fluorescein, a dye fre-
quently used for FP, has a lifetime of 4 ns and is thus only applica-
ble in FP assays in which a ligand of less than several thousand
daltons in size is labeled [12,13]. Considering that fluorescein itself
has a molecular weight of >300 Da, it seems quite conceivable that
labeling alters the ligand’s binding behavior.
In contrast to the aforementioned methods, surface plasmon
resonance (SPR) is not performed in free solution. Instead, it relies
on immobilizing one of the binding partners to a thin noble metal
film. Light at the resonance wavelength is used to induce surface
plasmons. When a binding partner binds to the immobilized bio-
molecule layer, the refractive index increases and therefore the
resonance frequency changes. The technique allows for real-time
determination of on- and off-rates and covers affinities from sub
nM to low mM with an intermediate throughput rate. Mass trans-
port as well as rebinding are well-described complications for ki-
netic measurements [14,15]. Establishing new assays for surface-
bound techniques like SPR can be time-consuming. Furthermore,
surface immobilization may affect the bound molecules’ dynamics
and thus alter the binding event [16].
As a solution-based method, microscale thermophoresis avoids
such surface artifacts and immobilization procedures. In standard
MST, one binding partner is fluorescently labeled [17]. However,
protein interactions can also be analyzed using label-free MST
which utilizes the intrinsic UV-fluorescence of proteins [18]. MST
relies on binding-induced changes in thermophoretic mobility,
which depends on several molecular properties, including not only
size, but also charge and solvation entropy [19]. Therefore, MST
does not require a change in size or mass like FP and SPR and is
not limited by the molecular weight ratio of the binding partners
like DLS. This does not only lead to a wider applicability but also
to a greater flexibility in assay design. Applicability and flexibility
are further enhanced by the fact that virtually any type of buffer
as well as complex bioliquid can be used.
2. The concept of microscale thermophoresis
2.1. Experimental approach
2.1.1. The MST instrument
Microscale thermophoresis is an all-optical approach to charac-
terize the properties of biomolecules. Visible light is used for fluo-
rescence excitation in the Monolith NT.115 MST instrument, for
which three types of LED-filter combinations are available: blue
(excitation 460–480 nm, emission 515–530 nm), green (excitation
515–525 nm, emission 560–585 nm) and red (excitation 605–
645 nm, emission 680–685 nm). In the Monolith NT.LabelFree
instrument an excitation wavelength of 280 nm and an emission
of 360 nm are used to, respectively excite and detect the intrinsic
UV-fluorescence of proteins. As illustrated in Fig. 1A, an infrared
(IR) laser with a wavelength of 1480 nm is coupled into the light
path of fluorescence excitation and emission. The IR radiation is
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focused onto the sample to exactly the spot where fluorescence
intensity is measured. The IR radiation is absorbed by the water
molecules of the sample buffer to create a temperature gradient.
As the coherent laser radiation can be easily focused, the tempera-
ture gradient is localized and strong while the overall temperature
remains low. The temperature increase has a 1/e extension of
25 lm, and a total volume of 2 nl of the sample is heated by typi-
cally 1–6 K, depending on IR-laser power and sample capillary
type. The height of the capillaries is tightly regulated to guarantee
highly reproducible temperature gradients. The capillaries have a
constant inner and outer diameter and are made from highly pure
glass. This ensures that a constant amount of laser power is ab-
sorbed, that the conductive heat transport through the glass is con-
stant and that no diffraction of laser radiation occurs. Other
important capillary properties are discussed separately in
Section 2.1.4.
2.1.2. Fluorescent labels
The thermophorectic movement is detected through fluores-
cence of one of the binding partners, originating either from an
attached fluorescent label or fluorescent fusion protein or from
protein intrinsic UV-fluorescence.
Crosslinker reactive groups are commonly used for protein
labeling. The fluorescent dye is coupled to the crosslinker, which
covalently binds to specific functional groups of the protein. For in-
stance, N-hydroxysuccinimide (NHS) esters react with primary
amines of lysine side chains or at the protein’s N-terminus. Cou-
pling to arginine’s guanidino group is possible as well. Alterna-
tively, maleimide dyes can be used to label sulfhydryl groups
present in reduced cysteine residues. In both cases, unreacted
dye needs to be removed prior to the binding analysis. Biomole-
cules typically contain more than one of these potential labeling
sites. However, the exact position of the fluorescent label is not
important for thermophoretic analysis. Furthermore, the presence
of labels at random positions adds to MST’s robustness, as it min-
imizes possible local effects of a label on the binding behavior.
Coupling reactions often require a specific pH, but the conditions
are normally well-tolerated by most proteins. Besides proteins,
other types of molecules can be fluorescently labeled to study
binding interactions (e.g. nucleic acids, sugars, lipids, etc.).
Alternative fluorescent labeling approaches can be used to spe-
cifically label the target protein without the need for prior purifica-
tion. In vitro translation systems allow for the linkage of
fluorophore-puromycin conjugates to the C-terminus [20] or the
incorporation of ‘‘non-natural amino acids’’. These amino acids
can already carry a fluorescent dye [21] or can be specifically mod-
ified after incorporation [22]. In addition, recombinant proteins can
be used directly in cell lysate. Either fusions to a fluorescent pro-
tein, such as the green fluorescent protein (GFP), can be used or
specific peptide sequence tags allowing for site-specific dye cou-
pling. Sample volumes and concentrations obtained by such pro-
tein purification-free approaches typically suit the requirements
of MST experiments very well.
Fluorescent labels provide high sensitivity such that sub-nM
concentrations can be used. They also ensure selectivity for mea-
surements in complex fluids or mixtures of molecules carrying dif-
ferent labels. It is however possible that fluorescent labels
influence certain binding interactions. Some biomolecules, such
as most membrane proteins (e.g. G protein-coupled receptors),
are particularly sensitive to modifications. A solution to this is la-
bel-free MST which utilizes intrinsic protein fluorescence in the
UV-range, arising from the aromatic amino acids tyrosine, phenyl-
alanine and tryptophan (Trp) with the latter being the dominant
intrinsic fluorophore. To get a measurable UV-fluorescence signal
in label-free MST, proteins of average Trp-content (2 or more
Trp) can typically be used in concentrations as low as 100 nM. A
protein concentration of 100 nM allows to precisely quantify
KDsP 50 nM, whereas smaller KDs can still be detected but not
accurately quantified [18].
The choice of source of fluorescence should take into account
the nature of the liquid in which the MST analysis will be per-
formed. Background fluorescence of the buffer at the fluorophore
wavelength should be avoided to obtain a good signal to noise ra-
tio. Therefore, label-free measurements cannot be conducted in
complex bioliquids such as concentrated cell lysate or blood serum
since these show a high background UV-fluorescence due to their
high protein content. Red fluorescent labels are the best choice
for measuring in serum as its background fluorescence is very
low at the red end of the spectrum. The fluorescence intensity
should be high enough to keep the concentration of the non-ti-
trated fluorescent binding partner in the order of the expected KD
or below. This ensures maximum resolution and highest precision
when determining dissociation constants.
2.1.3. The serial dilution
MSTmeasures equilibriumbinding events. For this, the non-fluo-
rescent partner is titrated against a fixed concentration of the fluo-
rescent partner. The initial fluorescence intensity should be
constant throughout the serial dilution unless the fluorophore is
close to the binding sites or there are problems with aggregation
or surface adsorption. To clarify this, the influence of detergents or
BSA and a negative control of the protein should be tested. Changes
in the fluorescence intensity in label-free MST should be treated
carefully, as the non-negligible background fluorescence in the
UV-range makes the measurements more susceptible to false-
positive signals arising merely from fluorescence changes. Thus,
background subtraction and negative controls are very important.
The available monolith series instruments accept up to 16 cap-
illaries for one experiment. The minimal concentration of titrated
partner needs to be sufficiently low to measure the thermophoretic
movement of the unbound state. The maximal concentration has to
be higher than the expected dissociation constant to reach satura-
tion of the fully bound complex. As a rule of thumb this is about
20-fold above the dissociation constant.
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Fig. 1. Microscale thermophoresis. (A) MST setup. The sample solution inside a
capillary placed on a temperature-controlled sample tray (TC) is locally heated with
an IR-laser (IR), which is coupled into the path of fluorescence excitation and
emission with an IR reflecting ‘‘hot’’-mirror (HM). FO: fluorescence observation;
OBJ: objective. (B) Schematic representation of the fluorescence time trace recorded
by the MST instrument. A series of processes can be separated from each other: The
initial fluorescence (I) drops fast as soon as the heating IR-laser is turned on (t = 5 s).
This T-jump (II) on a 100 ms timescale depicts the fluorophore’s temperature
sensitivity. It can easily be separated from the following diffusion-limited thermo-
phoresis (III) lasting several seconds. Both T-jump and thermophoresis can be
influenced by a binding event. Turning off the IR-laser (t = 35 s) leads to the inverse
T-jump (IV) and the backdiffusion (V). The fluorescence after thermodiffusion (F1) is
normalized to the fluorescence F0 which is either the initial fluorescence (depicted
here) or the fluorescence after the T-jump. In the former case shown here,
thermophoresis and T-jump are both included in the signal analysis whereas in the
latter, only thermophoresis is captured.
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2.1.4. Capillaries
Having prepared the serial dilution, the samples are filled into
capillaries through capillary action. Sample volumes of less than
4 ll are sufficient resulting in low sample consumption. MST cap-
illaries have precisely defined dimensions with inner diameter
variations of less than 1 lm guaranteeing highly reproducible tem-
perature gradients. The temperature gradient and the overall tem-
perature increase also depends on the thickness of the outer layer
of glass since its heat conductivity determines the efficiency of
heat transport away from the focal IR-laser area. The inner capil-
lary surface greatly influences the quality of the measurement.
Standard MST capillaries (NanoTemper Technologies) are physi-
cally treated to obtain a highly homogeneous surface and thus a
low background signal. Unspecific adsorption of one of the binding
partners to the capillary surface is readily detected by the MST de-
vice. It can be avoided by using capillaries coated with hydrophilic
or hydrophobic polymers or by using buffer additives like deter-
gents or proteins (e.g. BSA). When using BSA for small molecule
measurements, control experiments are recommended to rule
out unspecific binding of the small molecule to BSA.
2.2. Theoretical background
2.2.1. Thermophoresis
The directed movement of particles in a temperature gradient,
thermophoresis, was already described by Carl Ludwig in 1856
[23]. Thermophoresis can be depicted as a molecular flow, which
is directly proportional to the temperature gradient with the pro-
portionality constant DT, the thermal diffusion coefficient:
j ¼ cDT grad T
j: molecular flow; c: molecule concentration; DT: thermal diffusion
coefficient; T: temperature.
In steady state this thermophoretic flow is counterbalanced by
mass diffusion:
j ¼ D grad c
D: diffusion coefficient.
The thermophoretically induced change in concentration is
then determined by the ratio of D and DT which is referred to as
the Soret coefficient ST:
ST ¼ DDT
For a given spatial temperature difference DT the steady state
concentration change is therefore given by:
chot
ccold
¼ expðSTDTÞ
chot: molecule concentration in the hot area; ccold: molecule concen-
tration in the cold area.
This thermophoretic depletion depends on the interface be-
tween molecule and solvent. Under constant buffer conditions,
thermophoresis probes size, charge, solvation entropy and confor-
mation of the molecules. As biomolecular binding events typically
affect at least one these parameters, thermophoresis can be used as
a flexible tool for biomolecular affinity quantification [19].
2.2.2. MST signal analysis
The MST instrument excites and records fluorescence of the
focal IR-laser area within the sample before, during and after the
laser is turned on. As thermophoresis is diffusion limited, the spa-
tial restriction of the temperature gradient, achieved by using an
IR-laser for heating, allows for short measurement times well be-
low 30 s per sample. The fluorescence time trace, schematically
represented in Fig. 1B, displays a series of defined and separable
processes, each of them containing different information on the
binding event.
Before heating, the initial fluorescence (region I in Fig. 1B) is
recorded. It should be constant for all samples. Minor random
variations due to pipetting errors do not influence the result, as a
relative fluorescence signal is used. Occasionally, changes of the
initial fluorescence occur due to binding close to the fluorophore.
Having carefully ruled out artifacts as a possible reason (see Sec-
tion 2.1.3.), the KD may already be inferred from these changes in
some cases by plotting the initial fluorescence against the concen-
tration of the titrant and fitting to a binding model (see below).
Turning on the IR-laser leads to an abrupt change in fluorescence
intensity. This so-called temperature jump (T-jump, region II in
Fig. 1B) corresponds to the temperature-dependent change of fluo-
rescence, an inherent property of the fluorophore [24]. This tem-
perature dependence is sensitive to the fluorophore’s local
environment. Thus the T-jump can be influenced by conforma-
tional changes or binding in close proximity to the fluorophore
[25] which may provide spatial information on the binding site.
The T-jump occurs on the same short timescale of several 100 ms
as the fast heating by the IR-laser. It can thus easily be separated
from the following relatively slow thermophoresis (region III in
Fig. 1B) which, as a diffusion-limited process, lasts several seconds.
The thermophoretic motion creates a concentration gradient of the
fluorescent molecules. Fluorescence intensity reaches a plateau
representing the steady state in which thermodiffusion is counter-
balanced by mass diffusion. Immediately after the heating laser is
turned off, the fluorescence recovery due to the fluorophore’s tem-
perature dependence, the inverse T-jump (region IV in Fig. B), indi-
cates cooling of the sample. Finally, backdiffusion (region V in
Fig. 1B), driven by pure mass diffusion, leads to the compensating
of the concentration gradient.
As mentioned above, relative fluorescence is used to quantify
binding via MST:
Fnorm ¼ F1F0
Fnorm: normalized fluorescence; F1: fluorescence after thermodiffu-
sion; F0: initial fluorescence or fluorescence after T-jump.
F1 refers to the fluorescence measured several seconds after the
IR-laser has been turned on, when the traces of unbound and
bound state can be discriminated. The steady state does not neces-
sarily have to be reached within the time of the experiment [17]. F0
refers to either the initial fluorescence or the fluorescence after the
T-jump which is approximately 1 s after the laser has been turned
on. In the former case depicted in Fig. 1B, thermophoresis and T-
jump are both included in the signal analysis whereas in the latter,
only thermophoresis is captured. When the T-jump is influenced
by the binding event, including it leads to a better signal to noise
ratio in the resulting binding curve. Analysis of thermophoresis
with and without T-jump typically yields the same result. Both
processes should, however, not be used for a combined analysis
when their binding-induced changes show amplitudes with an
opposite sign and would thus cancel each other out.
For small relative temperature and concentration changes as is
the case in MST experiments, the above mentioned equation
describing the concentration change due to thermophoresis can
be approximated by linearization:
chot
ccold
¼ expðSTDTÞ  1 STDT
Fnorm corresponds to ST, plus where applicable the additional
contribution of the fluorescence change due to the fluorophore’s
temperature dependence dF/dT:
Fnorm ¼ 1þ dFdT  ST
 
DT
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Affinity is quantified by analyzing the change in Fnorm as a func-
tion of the concentration of the titrated binding partner. As the
thermophoretic movement of bound and unbound state superpose
linearly, the fraction bound (FB) is described by:
Fnorm ¼ ð1 FBÞFnorm; unbound þ ðFBÞFnorm; bound
FB: fraction bound; Fnorm, unbound: normalized fluorescence of
the unbound state; Fnorm, bound: normalized fluorescence of the
bound state.
In many cases the binding event can be described by a simple
model according to the law of mass action. More complex binding
modes require different models, e.g. the Hill equation for coopera-
tivity. It would be beyond the scope of this review to discuss differ-
ent binding models in detail. Thus the often applicable model
according to the law of mass action will be described in the follow-
ing. The binding process of a partner A and a partner B leading to
the formation of a complex AB is characterized by:
Aþ B¡ AB
A: binding partner A; B: binding partner B; AB: bound complex
of A and B.
The equilibrium dissociation constant KD which quantifies the
binding affinity is defined as:
KD ¼ ½Afree½Bfree½AB
KD: equilibrium dissociation constant; [A]free: concentration of free
partner A; [B]free: concentration of free partner B; [AB]: concentra-
tion of bound complex of A and B.
As the free concentrations are not known, total concentrations
are used instead. The total concentration of A and B are defined as:
½A ¼ ½Afree þ ½AB and ½B ¼ ½Bfree þ ½AB
Thus
KD ¼ ½Afree½Bfree½AB ¼
ð½A  ½ABÞð½B  ½ABÞ
½AB
In the following, Awill represent the titrated partner, B the part-
ner, whose concentration is kept constant and whose fluorescence
is read out. To obtain the KD from the MST data, we solve for the
fraction bound of B, FB:
FB ¼ ½AB½B ¼
½A þ ½B þ KD 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ð½A þ ½B þ KDÞ2  4½AB
q
2½B
FB is now expressed as a function of the total concentration of A
and B with the KD being the single free parameter. Fnorm from the
MST measurement linearly reports FB and can thus directly be fit-
ted to this equation.
Fnorm is plotted on a linear y-axis in per mil (‰) against the total
concentration of the titrated partner on a log10 x-axis. The advan-
tage of this semi-log plot is, that the binding data can be easily in-
spected by eye: the curve shows a characteristic s-shape (or
mirrored-s-shape) in which the unbound and saturated state build
a lower and upper plateau. Fnorm of the unbound state is revealed
by the fit and can be subtracted as a baseline value to yield DFnorm,
as depicted in the figures in this manuscript.
The plots showmeanDFnorm-values resulting from independent
repeats of the MST experiment. The error bars on individual data
points represent the standard deviation between these repeats.
The means are fitted and the resultant KD-values are given together
with an error estimation from the fit. The fitting procedure as-
sumes a Gaussian, symmetric error distribution. Thus the error
can reach negative values, if the sensitivity limit determined by
the lowest detectable concentration of fluorescent partner is
reached. In these cases, the KD-values are presented as an upper
limit and can also be lower.
2.3. Summary: assay optimization
MST experiments can easily be optimized as any potential prob-
lems are immediately revealed during assay design and specific
troubleshooting steps are available. Although some points have al-
ready been mentioned in the last paragraphs, this section summa-
rizes and details the information on optimization. The list is
certainly not exhaustive but can serve as a practical guide for users.
Surface adsorption to reaction tubes, pipette tips or glass capillar-
ies (‘‘Sticking’’):
Indications:
 If the capillary scan in the MST-instrument shows asymmetric
peaks, peaks with shoulders or double peaks, the labeled
material is most likely sticking to the capillary walls. Some-
times it takes several minutes before this is observed, some-
times it is not observable at all even though it is taking place.
 The fluorescence strongly drops along the titration curve as one
of the partners or the complex sticks.
 The fluorescence of the sample is much lower than expected
when compared to a calibration curve of the dye in the mea-
surement buffer.
 The fluorescence of the same sample decreases much faster
over time than would be explained by bleaching.
 The raw data curves of multiple measurements of an identical
sample strongly deviate.
Optimization:
 Use low-binding reaction tubes and pipette tips.
 Use capillaries coated with hydrophilic or hydrophobic
polymers.
 Use buffer additives like detergents or proteins, e.g. BSA. When
testing small molecules, binding to BSA has to be excluded
experimentally.
Aggregation:
Indications:
 The raw data curves show bumps or waves.
 The raw data curves of multiple measurements of an identical
sample strongly deviate.
Optimization: improve sample stability, quality and homogeneity
by
 spinning down the sample before the experiment (e.g. 5 min at
15000  g) and only using the supernatant;
 using buffer additives like detergents or proteins;
 optimizing the buffer in general (ionic strength, pH, etc.)
Suboptimal fluorescence intensity:
Indications:
 Low signal to noise ratio in fluorescence intensity during the
capillary scan and in the raw data curves.
 The upper parts of the peaks in the capillary scan are cut-off or
there is no raw data curve but a flat line as the upper limit of the
dynamic range of the fluorescence detection is exceeded (2500
counts on the current model of NT.115, see manual).
 The fluorescence of the sample is much higher or lower than
expected.
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Optimization:
 Test for free dye (high fluorescence intensity) or low labeling
efficiency and loss of material (low fluorescence intensity)
during the labeling process e.g. by photometrically determin-
ing the dye and protein concentration.
 Adjust the LED-power or concentration of the fluorescent bind-
ing partner to yield a fluorescence intensity between 200 and
1500 counts. The optimal concentration and LED-setting can
be found before the binding measurement by preparing a dilu-
tion series of the fluorescent partner in the measurement buffer.
Suboptimal concentration range in the serial dilution:
Indications:
 No binding is observed.
 The plateau of the unbound state or the saturation of the fully
bound state are not reached.
Optimization:
 Optimize the concentration range of the titration, e.g. by using
the concentration finder of the Nanotemper-Analysis-Software.
 When the highest possible concentration of one binding
partner is below saturation levels (e.g. due to solubility
problems) reversing the assay design might be helpful.
Low signal to noise ratio in MST signal amplitude:
Indication:
 The binding-induced change in the MST signal can barely or not
at all be discriminated from the background fluctuation.
Optimization:
 Improve the quality of the sample by optimizing the buffer or
spinning down the sample before the experiment (e.g. 5 min
at 15000  g) and only using the supernatant.
 Increase the IR-laser power to use a higher temperature
gradient.
 Reverse the assay design.
 Increase the activity of the fluorescent sample.
3. Material and methods
3.1. TEM1-BLIP
Wt-TEM1 was labeled using the Monolith NT Protein Labeling
Kit RED (NanoTemper Technologies) according to the supplied pro-
tocol. The concentration of labeled TEM1 or Ypet-wt-BLIP was kept
constant at 10 nM. The corresponding unlabeled binding partner
was titrated in 1:1 dilutions, with the highest final concentration
chosen about 20-fold above the KD expected from previously pub-
lished SPR results. Thus the highest final concentrations were
250 nM wt-BLIP, 6 lM W112A-BLIP and 11 lM W150A-BLIP for
the experiments with wt-TEM-NT647. For the measurements with
Ypet-BLIP, maximum concentrations of 2 lM wt-TEM and 7.5 lM
R243A-TEM were used in buffer, 250 nM TEM in lysate.
A 50 mM Tris–HCl buffer, pH 7.6 containing 150 mM NaCl,
10 mM MgCl2 and 0.05% Tween-20 was used. For the measure-
ments in cell lysate, 20  106 millions 293T cells were lysed in
500 ll RIPA-buffer and centrifuged at 15,000  g for 5 min to re-
move large aggregates and cell debris. Ypet-BLIP was diluted in
200 ll lysate to a final concentration of 20 nM and mixed with
the TEM1 dilution series in buffer to yield a final Ypet-BLIP concen-
tration of 10 nM in 50% lysate.
Measurements were performed in standard treated capillaries
(NanoTemper Technologies) on a Monolith NT.115 system (Nano-
Temper Technologies) using 50% LED and 80% IR-laser power. Laser
on and off times were set at 30 s and 5 s, respectively.
3.2. RON2-AMA1
MST experiments were performed on a Monolith NT.115 system
(NanoTemper Technologies) using 100% LED and 20% IR-laser
power. Laser on and off times were set at 30 s and 5 s, respectively.
Recombinant His-tagged AMA1 (His-AMA1) was expressed in
Pichia and purified on a nickel column as previously described
[3]. The protein was labeled with NT647 (NanoTemper Technolo-
gies) and applied at a final concentration of 25 nM. Both unlabeled
RON2 peptide and biotinylated RON2 peptide were synthesized by
LifeTein LLC (South Plainfield, NJ). A twofold dilution series was
prepared for the unlabeled RON2 in DMSO. Subsequently, 0.5 ll
of each dilution point was transferred to 9.5 ll labeled AMA1-solu-
tion, with the final RON2 concentration ranging from 50 lM to
1.5 nM, thus maintaining the DMSO concentration at 5% constant
sample-to-sample. Samples were filled into hydrophilic capillaries
(NanoTemper Technologies) for measurement. FITC labeled RON2
peptide was obtained from Peptide 2.0 (Chantilly, VA), further dis-
solved in DMSO to produce a 20 lM stock solution and applied at a
final concentration of 10 nM. A twofold dilution series was pre-
pared for unlabeled His-AMA1 in PBS and each dilution point
was similarly transferred to FITC-RON2 solution. The final concen-
trations of His-AMA1 ranged from 7.8 lM to 0.24 nM. Samples
were filled into standard treated capillaries (NanoTemper Technol-
ogies) for measurement.
SPR experiments were performed on a ProteOn XPR36 system
(Bio-Rad, Hercules, CA) at 25 C using PBS with 0.005% Tween-20
as the running buffer. Immobilization of the His-AMA1 protein
was achieved at 30 ll/min on an HTE chip. Samples of the unla-
beled RON2 peptide were prepared at final concentration of
500, 167, 55, 18.5 and 6.2 nM and were injected at 30 ll/min in
each horizontal channel. Association was monitored for 2 min,
dissociation for 10 min. In a separate experiment, immobilization
of the biotinylated RON2 (b-RON2) peptide was achieved on a
NLC chip at 100 ll/min. Samples of the His-AMA1 protein were
prepared at 300, 100, 33, 11 and 3.7 nM and were injected at
30 ll/min in each horizontal channel. Association was monitored
for 2 min, dissociation for 30 min. Kinetic titration data were pro-
cessed in ProteOn Manager by concatenating the responses of all
five analyte concentrations, and by globally fitting to either a sim-
ple Langmuir binding model without mass transfer or a heteroge-
neous ligand model using both buffer blank and interspot as
references.
FP experiments were performed on a Viewlux™ high-through-
put charge-coupled device (CCD) imager (PerkinElmer, Waltham,
MA) using an excitation filter of 480 nm and an emission filter of
540 nm. His-AMA1 was serially diluted in PBS with 0.01% Tween-
20 (final concentration: 7.8 lM to 0.24 nM) and mixed with
20 nM FITC-RON2 peptide (final concentration) in a 384-well
Greiner (Monroe, NC) solid bottom assay plate. Plates were read
after 5 min incubation at room temperature. For the reverse titra-
tion, biotinylated RON2 peptide was serially diluted in the same
buffer (final peptide concentration started at 100 nM) and was
mixed with 25 nM (final concentration) NT495-His-AMA1.
3.3. GPCR
A fusion construct of the rat neurotensin receptor 1, NTS1B,
with N- and C-terminal fusion partners, maltose binding protein
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and thioredoxin, respectively, was expressed and purified as de-
scribed by Attrill et al. [40], with the modification that the ligand
affinity column eluate was concentrated using a 1 mL HisTrap
Ni2+-column (GE Healthcare), and the eluate thereof was diluted
in imidazole- and salt-free buffer (50 mM Tris pH 7.4, 0.1% dodecyl
maltoside (w/v), 0.01% cholesteryl hemisuccinate (w/v), 10% glyc-
erol (v/v)) to lower the imidazole concentration to 85 mM and
the sodium chloride concentration to 50 mM in the final sample
to allow salt-sensitive ligand binding, giving a final receptor con-
centration of 2.5 lM as determined from A280 and gel electro-
phoresis against BSA standards. SR48692 was obtained from
Sanofi-Aventis and neurotensin was purchased from Sigma Al-
drich. A N-terminal cysteine derivative of neurotensin (Alta Biosci-
ence, Birmingham) was labeled with AlexaFluor488 (Sigma
Aldrich) by mixing the dye with a threefold excess of the peptide,
adjusting the pH to 7 and incubating for 1 h at room temperature.
The labeled compound was purified by HPLC using a 20–60% ace-
tonitrile gradient on a semi-preparative C18 column. Labeling
and purity were verified by mass spectrometry. Neurotensin-
A488 was lyophilised and subsequently stored in 50 mM Tris pH
7.4.
Twofold dilution series starting at 375 nM NTS1B in the stan-
dard MST experiments and 2.5 lM neurotensin as well as 25 lM
SR48692 in the label-free MST experiments were prepared in the
following buffer: 50 mM Tris pH 7.4, 0.1% dodecyl maltoside
(w/v), 0.01% cholesteryl hemisuccinate (w/v), 10% glycerol (v/v),
imidazole 85 mM and sodium chloride 50 mM. Neurotensin-
Alexa488 was used at 25 nM, while NTS1B was used at 150 nM.
As a control, the SR48692-dilution was tested against a constant
concentration of 150 nM thermally denatured NTS1. Due to the
fact that concentrations of the receptor in label-free MST experi-
ments were above the KD, the determined KD is a lower limit and
affinity can be higher. Lowering receptor concentration will in-
crease resolution. Please note, in label-free experiments the detec-
tion limit (i.e. minimum concentration of the fluorescent molecule)
depends not only on the number of tryptophanes, but also on their
respective position in the protein. Typically, concentrations as low
as 100 nM can be used [18]. The fit to the quadratic solution of the
law of mass action allows to determine even higher affinities than
that with high precision.
In the competition experiment, a constant neurotensin concen-
tration of 1 lM was used and SR48692 was diluted 1:1 starting at
50 lM. Label-free experiments were performed at 20% LED and
40% IR-laser power, standard MST experiments at 90% LED power
and 20% IR-laser power. Laser on and off times were set at 30
and 5 s, respectively.
The A2aR was stored and measured in 50 mM K-HEPES pH 7.5
buffer containing 800 mM KCl, 10% glycerol, 0.05% dodecyl malto-
side (w/v) and 0.01% cholesterol hemisuccinate (w/v). The concen-
tration of A2aR was determined by measuring protein peak area in
an analytical size exclusion chromatogram, and comparing it with
protein standards. For the label-free MST experiments, A2aR was
used at a constant concentration of 250 nM when testing
theophylline-binding and 500 nM in all other experiments. The
ligands were added to the buffers in the required concentrations
from a 100 mM stock in DMSO. Twofold dilution series of the
ligands were prepared, starting at the following concentrations
and resultant maximum DMSO concentrations: 250 lM for amilo-
ride (2.5‰ DMSO), 100 lM for theophylline (0.1% DMSO), 1 mM
for caffeine (1% DMSO) and 5 lM for ZM241385 (0.05‰ DMSO).
For the competition experiments in presence of 250 lM amiloride,
twofold dilution series of caffeine starting at 2 mM and theophyl-
line (2% DMSO) starting at 1 mM (1% DMSO) were used. Prior to
measurement, ligands were incubated with protein for 10 min on
ice. Experiments were performed at 20% LED and 20% IR-laser
power with laser on and off times set at 30 and 5 s, respectively.
3.4. G9a
G9a was labeled with NT495 or NT647 dye (NanoTemper Tech-
nologies) and applied at a final concentration of 50 nM in 50 mM
Tris–HCl, pH 7.5, with 150 mM NaCl and 0.05% Tween-20.
BIX-01294 was obtained from Sigma–Aldrich (St. Louis, MO) and
further dissolved in dH2O to produce a 30 mM stock. A 16-point
twofold dilution series (in dH2O) of BIX-01294 was mixed with
G9a solutions to generate a final compound concentration ranging
from 500 lM to 15.3 nM. Peptides corresponding to the first 21N-
terminal amino acids of histone H3 followed by a GG linker and a
biotinylated lysine (b-H3(1–21)) were purchased from AnaSpec
(Fremont, CA). b-H3(1–21) was similarly diluted in dH2O and
mixed with labeled G9a to generate a final concentration ranging
from 183.6 lM to 5.6 nM. After 15-min incubation at room tem-
perature, samples were filled into standard treated capillaries
(NanoTemper Technologies) and MST measurements were per-
formed on a Monolith NT.115 (NanoTemper Technologies) using
100% LED (50% LED for NT647-G9a) and 20% or 40% IR-laser power.
Laser on and off times were respectively set at 30 and 5 s. For com-
petition experiments, labeled G9a was pre-mixed with a constant
concentration of b-H3(1–21) or S-adenosylmethionine (SAM) and
incubated at room temperature for 15-min. Either compound
was added at a concentration near its respective KD (determined
using MST for the peptide substrate or based on literature value
for SAM [67,69,70]): 2 lM b-H3(1–21) or 20 lM SAM. In a separate
experiment, either compound was added at a saturating level (15–
50-fold above its KD): 100 lM b-H3(1–21) or 300 lM SAM. The
same dilution series of BIX-01294 was added to the pre-formed
G9a-b-H3(1–21) or G9a-SAM complex, and MST was measured
after 15-min incubation at room temperature.
The interaction between G9a and BIX-01294 was also evaluated
using a label-free approach. Specifically, a 16-point serial dilution
of BIX-01294 was mixed with G9a (final concentration: 2 lM) with
BIX-01294 final concentration ranging from 200 lM to 6.1 nM.
Samples were filled into LabelFree standard treated capillaries
(NanoTemper Technologies) and measured on a Monolith
NT.LabelFree (NanoTemper Technologies) using 30% LED and 25%
IR-laser power. Laser on and off times were also set at 30 and
5 s, respectively.
4. Results and discussion
Studying protein interactions can be challenging in certain
cases. Problems arise from high mass ratios of the binding partners
as in the case of protein-small molecule interactions. Membrane
proteins are experimentally demanding, as they are hard to stabi-
lize in solution. Measuring cooperative and competitive binding
modes as well as working in biological liquids instead of simplified
buffers can be difficult. In the following we demonstrate that MST
is applicable under all mentioned challenging conditions by show-
ing previously unpublished data and highlighting relevant exam-
ples from literature.
4.1. Protein–protein interactions
4.1.1. b-Lactamase TEM1 binds its inhibitor BLIP
Protein–protein binding is mainly based on specific non-cova-
lent interactions at the binding partners’ interfaces. The contribu-
tion of different amino acid residues can be elucidated by
quantifying the influence of site-specific mutations. An in this
respect well-characterized system is the binding of b-lactamase
TEM1 to the b-lactamase inhibitory protein BLIP. Herein, we inves-
tigated the binding of TEM1 b-lactamase to BLIP using MST.
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In a first set of experiments, we used a constant concentration
of NT647-labeled wild-type TEM1 (wt-TEM1). Binding to wild-type
BLIP (wt-BLIP) as well as to two BLIP mutants with substitutions of
a tryptophan residue at position 112 or 150 by alanine (W112A-
BLIP, W150A-BLIP) was quantified. MST yielded a KD of
3.8 ± 0.8 nM for the interaction of the wt-proteins (Fig. 2A). As ex-
pected, the alanine substitutions within BLIP resulted in reduced
affinities for TEM with a KD of 0.5 ± 0.1 lM in the case of
W112A-BLIP and a KD of 1.7 ± 0.4 lM in the case of W150A-BLIP
(Fig. 2B and C). Due to limited sample amounts W150A-BLIP satu-
ration was not fully reached which affects the precision of the fit.
Nonetheless, both results are in excellent agreement with the liter-
ature values of 3.2 ± 0.6 nM (wt) [26], 0.36 ± 0.06 lM (W112A) and
3.8 ± 0.6 lM (W150A) [27] determined by SPR. Remarkably, the
thermophoretic signal seems to contain further information on
the binding event. Upon binding of wt-BLIP and W112A-BLIP to
TEM1, the complex shows an increased depletion compared to
the unbound TEM1, represented by the negative slope of the bind-
ing curve (Fig. 2A and B). Binding of W150A-BLIP has the opposite
effect (Fig. 2C). As described by Wang et al., the W150A mutation
in BLIP leads to a pronounced conformational rearrangement, thus
to defects in geometrical shape complementarity to TEM1 and
trapping of additional water molecules in the TEM1-BLIP interface.
Therefore, the enthalpic driving force for binding decreases [28].
This conformational change likely causes the reversal in sign of
the MST-amplitude.
We also used an alternative labeling approach in combination
with the reversed titration protocol. The fluorescent fusion protein
Ypet-wt-BLIP was kept constant while wt-TEM1 and R243A-TEM1
(substitution of arginine at position 243 to alanine) were titrated
(Fig. 2D). For the interaction of the wt-proteins a KD of 5 ± 2 nM
was determined which does not only reproduce the literature va-
lue (3.5 ± 0.5 nM, SPR) [29] but also the result measured via the re-
versed assay design. The R243A-TEM1 mutant showed a reduced
affinity for BLIP (KD = 0.19 ± 0.05 lM) which is consistent with lit-
erature [30]. As measurements in buffer do not resemble the highly
crowded, intracellular environment, we also performed MST in
mammalian cell lysate. Under these close to in vivo conditions, a
KD of 10 ± 4 nM was determined for the binding of Ypet-wt-BLIP
to wt-TEM1. This demonstrates the applicability of MST for affinity
quantification of protein–protein interactions, not only in buffer,
but also in cell lysate.
4.1.2. Grb2 dimerization
Grb2 is known as an adaptor protein involved in several signal
transduction pathways [31]. An additional function has been re-
cently suggested: Grb2 dimers seem to control the activity of the
receptor tyrosine kinase FGFR2 in the absence of extracellular
stimuli by growth factors [1].
The dimerization of Grb2 was analyzed via MST. Fluorescently
labeled Grb2 at a constant concentration of 100 nM was added to
a serial dilution of unlabeled Grb2 ranging from 55 nM to
100 lM. A KD of 0.65 ± 0.08 lMwas determined for Grb2 dimeriza-
tion (Fig. 3). DLS experiments indicate that the dimer is the pre-
dominant form from 40 down to 0.4 lM, whereas below that
concentration, the monomer was present [1]. The MST result is
consistent with DLS, which as discussed in Section 1.2. is most reli-
able when studying the interaction of small, equally sized mole-
cules as it merely detects changes in the hydrodynamic radius.
Also, when measuring dimerization, MST is comparable to DLS in
that the twofold size increase is likely to be the major cause of
the decrease in thermophoretic mobility. In general, quantification
of a dimerization process is not trivial. Although dimerization
can also be quantified via a dilution approach in ITC for KDs in
the lM-range [32], the technique is not feasible for higher dimer-
ization affinities. ITC requires minimal protein concentrations in
the lM-range to get a measurable heat change [8]. If the dimeriza-
tion KD lies in the sub-lM range as for Grb2, nearly all of the
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Fig. 2. MST quantifies the TEM1-BLIP interaction in agreement with SPR literature values. (A) By fitting the change in thermophoretic depletion upon titration of wt-BLIP to a
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protein is present as dimers at this lowest detectable concentration
(Fig. 3). Thus the monomeric state and the monomer–dimer-tran-
sition are not captured and the KD is not measurable via ITC.
4.2. Protein-peptide interaction: AMA1 and RON2
The invasion of red blood cells by the malaria-causing parasite
Plasmodium falciparum is critically dependent on the interaction
of two parasite proteins, RON2 and AMA1 [3,33,34]. To quantify this
interaction, the binding between a short RON2 peptide and AMA1
was extensively characterized using MST, SPR and FP. The RON2
peptide represents a conserved region among all P. falciparum
isolates with known sequence; in this region, two completely con-
served cysteine residues forming a disulfide bridge have been
determined to be essential for binding to AMA1, as mutation or
alkylation abolished binding [3].
We used two MST-assay designs for the AMA1-RON2 interac-
tion: titration of AMA1 to a constant concentration of RON2-FITC
and titration of RON2 to a constant concentration of AMA1-
NT647. When titrating AMA1, the MST signal shows a single
binding event with a KD of 28 ± 2 nM. In contrast, the titration of
RON2 yielded an MST signal in which the high affinity binding is
superimposed by a second binding event at higher RON2 concen-
trations. When quantifying the high-affinity binding from these
data, we restricted the fit to the first half of data points yielding
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a KD of 62 ± 16 nM. Fitting the low-affinity binding yielded
KD = 1.4 ± 0.2 lM. We also analyzed all data points with a fit
assuming two independent binding events with different KDs,
where we used the simplification that both binding events have
the same signal amplitude. This fit yielded KDs of 81 ± 21 nM and
1.2 ± 0.1 lM.
The KD determined for the high-affinity AMA1-RON2 interac-
tion varies for the different MST designs. This is because in case
of the biphasic signal, the high-affinity KD is either determined
by fitting less data points or by using a fit function with an addi-
tional parameter, the second low-affinity KD. Despite this limita-
tion, the KDs for the high-affinity binding lie in the double-digit
nanomolar range for both assay designs, which demonstrates the
method’s reversibility. However, the example also shows the
importance of performing the assay in both ways: while AMA1-
titration is needed to precisely quantify the KD, only the titration
of RON2 gave additional information on a second, low-affinity
binding event.
In SPR, when AMA1 was titrated against a constant level of
immobilized RON2, a KD of 13 ± 1 nM (Fig. 4C) was found. The
reversed assay design of titrating the same RON2 species as used
in MST experiments yielded a KD of 38.3 ± 0.4 nM (Fig. 4D). The dis-
sociation phase in the SPR data was best fit by a heterogeneous
ligand model, indicative of the same second, low-affinity binding
phase captured in (Fig. 4B and D).
This second binding event could be explained by the fact that
the unlabeled RON2 peptide might be present in two forms in solu-
tion: one with and one without a disulfide bond, i.e. a cyclized and
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Fig. 5. Label-free MST for quantification of GPCR NTS1B ligand binding. (A) Homology model of neurotensin receptor 1 (NTS1; Satita Tapaneeyakorn, Biomembrane structure
unit, University of Oxford) based on rhodopsin for the transmembrane regions and the b-adrenergic receptors for the loop regions viewed from the side (left) and top (right).
Residues involved in binding of neurotensin (W339, F344 and Y347, cyan), inverse agonist SR48692 (Y324, Y351, T354, F358 and Y359, green) or both (M208, F331 and R327,
magenta), as determined from mutagenesis studies [71], are highlighted. (B) Label-free MST utilizes NTS1B’s intrinsic Trp fluorescence to quantify the binding to neurotensin
(KD 6 20 nM). (C) In agreement with other biophysical techniques, MST using fluorescently labeled neurotensin yields a lower affinity (KD = 21 ± 20 nM). (D) Using label-free
MST, a KD of 15 ± 11 nM for the inverse agonist SR48692 was determined (black circles). Pre-saturating NTS1 with neurotensin right-shifts the KD for SR48692 to 640 ± 50 nM
(red squares). Denatured NTS1B did not show binding to SR48692 thus proving specificity (blue triangles).
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a linear from. As the second binding phase is not present in the
reversed assay design (Fig. 4A), the labeled RON2 seems to be
homogeneously cyclized.
An EC50 of 0.05 ± 0.01 lM was obtained by FP experiments
where AMA1 titration was performed against a constant concen-
tration of labeled RON2 as illustrated in Fig. 4E. As expected, the re-
versed assay design, in which biotinylated RON2 was titrated
against a constant level of labeled AMA1, yielded a much smaller
FP signal amplitude (Fig. 4F). This is because the FP signal ampli-
tude is largely based on the degree of binding-induced size change.
Nevertheless, the observed EC50 also lies in the double-digit nano-
molar range (77.1 ± 0.2 nM).
This AMA1-RON2 case study shows, firstly, that MST can yield
KD data very comparable to that obtained by other well-established
biophysical methods, including FP as a solution-based and SPR as a
solid-phase technique. All KDs lie in the double digit nM-range. SPR
yielded slightly higher affinities than MST. However, it has previ-
ously been described, that due to surface artifacts SPR tends to
overestimate the affinity compared to other techniques [35]. Sec-
ondly, the experiments also exhibited the ability of MST to detect
binding even when the assay was set up in a relatively less favor-
able manner in terms of size change upon binding: when the larger
molecule AMA1 (66 kDa) was labeled and was held constant, titra-
tion of the smaller peptide (4.3 kDa) yielded a similar high-affinity
binding phase as that obtained in the reverse titration. Thirdly, for
this particular system, fluorescent labeling of either binding part-
ner did not adversely affect the binding event, i.e. did not give
rise to a significant change in the KD or assay artifacts such as
non-specific binding to the fluorescent label. An interesting and
more specific aspect of this system is the observation of a second
binding phase that most likely reflects the prescence of both, a
cyclized and an linear form of the unlabeled RON2 peptide. How-
ever, difficulties associated with the production and handling of a
fully-reduced/linear peptide precluded us from performing care-
fully controlled experiments comparing MST and SPR responses
derived from fully-cyclized and fully- linear peptide counterparts;
thus, the proposed explanation for the observed biphasic behavior
remains speculative at this point. Overall, the AMA1-RON2 case
study illustrates that MST is a sensitive and versatile biophysical
technique for protein-peptide interaction studies. We note that
while the RON2 peptide represents a good model system to study
the interaction by a range of biophysical techniques without the
added encumbrance brought about by the need to produce a sec-
ond protein, these initial findings need to be further validated
through a study using the intact protein pair.
4.3. Analyzing GPCR membrane proteins NTS1 and A2aR
Membrane proteins make up a third of the proteome and con-
stitute the majority of drug targets. Their biological importance
notwithstanding, they are extremely challenging to work with. G
protein-coupled receptors (GPCR) are the largest class of mem-
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brane proteins encoded in the human genome [36] and share a
common architecture (Fig. 5A): a bundle of seven transmembrane
(7TM) helices connected by flexible loop regions. Even though
structural data is still scarce it has become apparent that while
the 7TM fold is conserved, there is remarkable structural diversity
particularly at the extracellular ligand binding side of the proteins
[37]. Clearly, a combination of structural knowledge, ligand dock-
ing [38,39] and fast and reliable technologies for measurement of
ligand binding affinities are necessary and indispensable tools for
next generation drug discovery efforts. Typically, ligand binding
of GPCRs is studied by radioligand binding assays. However, the
availability of radioligands is frequently a limiting factor. MST
could provide a good alternative to determining the affinities of li-
gands without the need for radioligands.
Neurotensin receptor 1 (NTS1) is one of the few class A GPCRs
that can be expressed in E. coli and purified in a functional, li-
gand-binding form [40]. Using MST we determined the binding
affinity of the tridecapeptide ligand neurotensin for a fusion con-
struct of NTS1, NTS1B [41]. Titrating NTS1B to AlexaFluor488-
labeled neurotensin gave a KD of 21 ± 20 nM (Fig. 5C). Due to
limited amounts of NTS1B protein, saturation could not be reached,
which affects the precision of the fit. Thus, we also used the re-
versed protocol yielding KD 6 20 nM (Fig. 5B). The intrinsic UV-
fluorescence of NTS1B was exploited and the ligand was titrated,
so that saturation was reached. The MST results are in good agree-
ment with previous SPR data showing a dissociation constant of
1–2 nM for the binding of neurotensin to an NTS1 fusion construct,
[42] while slightly lower affinities have previously been found for a
fluorescently labeled (TAMRA) neurotensin derivative by fluores-
cence correlation spectroscopy (KD = 7 ± 3 nM, Harding, unpub-
lished results), although other fluorophores did not affect the
affinity (KD = 1.4 nM for Cy5-neurotensin) [43]. KD dependence on
the choice of fluorophores has previously been observed for other
fluorescent ligand derivatives as well [44]. We also studied binding
of a known inverse agonist, SR48692, to NTS1B and obtained a KD
of 15 ± 11 nM using label-free MST (Fig. 5D). This value is in good
agreement with the affinities reported in literature obtained for
NTS1 in membrane extracts (KD  3-10 nM [45,46]). A competition
assay in which we added SR48692 to receptor pre-saturated with
neurotensin (1 lM) shifted the dissociation constant more than
an order of magnitude (KD = 0.64 ± 0.05 lM; Fig. 5D), confirming
specificity of binding and that both compounds compete for the
same binding pocket (Fig. 5A). Non-specific binding was further
excluded by performing a control experiment with denatured
receptor. Interestingly, binding of the agonist neurotensin has an
opposite effect on the thermophoretic depletion compared to bind-
ing of the inverse agonist SR48692. This could be due to the differ-
ent structures of the binding partners, however, considering the
small size of both ligands (<2 kDa) compared to the receptor
(100 kDa), it could even reflect the different structural effects the
agonist and the inverse agonist have on the receptor, with neuro-
tensin promoting conformational changes, while SR48692 locks
the receptor in an inactive conformation, giving rise to differences
in the hydration shell and thus in the thermophoretic properties of
the complex.
As a second type of GPCR, we tested the adenosine A2A receptor
(A2aR) expressed and purified as a fusion with apocytochrome
b562RIL as previously described [47]. We used label-free MST to
analyze the binding of three orthosteric antagonists, caffeine, theo-
phylline and ZM241385, and one allosteric ligand, amiloride. The
affinities for these ligands have been previously determined as
Ki = 18 lM for caffeine, [48] Ki = 14 lM for theophylline, [49,50]
Ki = 1.2 nM for ZM241385, [51] and Ki = 12 lM for amiloride (Kat-
ritch et al., manuscript in preparation). These Ki values are based
on heterologous competition of radioligands and inhibition of bio-
logical function and can thus only give an approximate indication
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of the KD determined via a direct, biophysical measurement like
MST. However, we obtained KDs that were in good accordance:
40 ± 17 lM for caffeine, 5 ± 2 lM for theophylline, 643 nM for
ZM241385 and 52 ± 7 lM (Fig. 6A) for amiloride (Fig. 6B). Amilo-
ride was not used at concentrations above 250 lM due to solubility
problems. This affects the precision of the fit. The signal amplitude
for the three orthosteric ligands was low. In contrast amiloride, an
allosteric ligand that binds to a different site from caffeine and the-
ophylline [51], induced a strong change in thermophoretic mobil-
ity, shown in Fig. 6B. Allosteric ligands are known to alter
receptor activity by inducing conformational changes [52]. As
amiloride is similar in size to the other tested ligands, the much
stronger change in thermophoretic mobility upon binding is likely
to be caused by this significant conformational change leading to a
reorientation of the receptor’s hydration shell. Addition of caffeine
and theophylline in presence of saturating amounts of amiloride
also had a strong but opposite effect on thermophoresis, indicating
non-competitive binding that also produced significant conforma-
tional change. Apparent KDs of 84 ± 10 lM for caffeine and
27 ± 6 lM for theophylline were derived. Hence, label-free MST
can also be used to investigate allosteric binding in GPCRs.
This study demonstrates that MST can be used as a quick, sen-
sitive tool to measure binding affinities for difficult systems such
as GPCRs which suffer from low expression yields and protein
instability. In addition to the pharmaceutical importance of know-
ing binding affinities, biophysical studies of membrane proteins of-
ten require truncations or addition of fusion partners to improve
stability and expression, or mutations to facilitate labeling for var-
ious techniques. Being able to easily assess the effect of these mod-
ifications on the ligand binding capacity to verify the validity of the
approach used is invaluable. In comparison to most commonly
used techniques, the low sample requirements and the simplicity
of the mix-and-read protocol make MST more suited for such rou-
tine binding affinity analyses. Compared to alternative techniques
such as SPR, MST suffers less from the need for rigorous buffer con-
trols, which can be problematic for membrane proteins in deter-
gent where the exact protein concentration and especially the
detergent concentration can be difficult to determine.
4.4. Cooperative binding within the ternary complex: synaptotagmin
Synaptotagmin-1 (syt1) is the main Ca2+-sensor for fast
calcium-regulated neurotransmitter release [53]. It binds five
Ca2+-ions with affinities ranging from 50 lM to 10 mM as mea-
sured by NMR and ITC [54,55]. Ca2+-binding was reproduced by
MST using hydrophobic capillaries and 2.5 mg/ml BSA in order to
overcome association of syt1 with the capillaries. An apparent
binding affinity of 210–230 lM was determined by MST [56,57].
Syt1 also binds to membranes containing anionic phospholipids
such as phosphatidylinositol 4,5-bisphosphate (PIP2) and this
binding is important for its function (Fig. 7A). Binding to PIP2 oc-
curs already in absence of Ca2+ as shown by membrane binding
co-sedimentation assays in density gradients with a cytoplasmic
fragment of syt1 and artificial liposomes [58]. However, precise
quantification of membrane binding is limited because co-
sedimentation assays do not report binding under equilibrium
conditions. This problem was overcome in a recent study where
Förster resonance energy transfer (FRET) was measured from
syt1 labeled with a donor fluorophore to liposomes tagged with
an acceptor fluorophore [59]. Since close proximity between the
two fluorophores is required for FRET (typically well below
5 nm), the results of FRET-based assays fundamentally depend on
the labeling positions and binding orientations of syt1 to the
membrane.
MST does not suffer from these limitations and allows to mea-
sure membrane binding under equilibrium conditions irrespective
of the precise labeling of syt1 (Fig. 7B). Indeed, binding of the
labeled syt1 to 100 nm-sized PIP2-containing liposomes resulted
in a clear change of the MST signal. As apparent from Fig. 7B, the
binding strength of syt1 to PIP2-containing liposomes was 5-fold
enhanced in the presence of Ca2+ with readily distinguishable
KD-values (50 ± 10 lM in the absence and 13 ± 3 lM in the pres-
cence of Ca2+). The addition of Ca2+ was the only change in an
otherwise identical MST assay design. Therefore, the change in
KD most likely reflects the influence of Ca2+ on the KD. Similar coop-
erative Ca2+ and PIP2 binding was previously observed with co-
sedimentation assays and FRET [55,58]. However, all these assays
(including the MST assay shown in Fig. 7B) suffer from the limita-
tion that Ca2+-binding is not directly measured, but only inferred
from binding to the liposomes. Thus, in these assays, Ca2+ and
PIP2 binding cooperativity can only be measured in case syt1 first
binds to (sufficient) Ca2+ prior to membrane binding (pathway
A2–A2 in Fig. 7A) and cannot be distinguished in case syt1 already
binds to PIP2 in absence of Ca2+ (pathway B1–B2).
In order to measure binding of Ca2+ to syt1 under saturating
conditions of PIP2, we adapted our MST assay and added PIP2
not incorporated into liposomes but directly to the capillaries.
Due to the high charge of PIP2 (between 3 and 5) [59] even
brain-isolated PIP2 (i.e. with long acyl chains) is water soluble up
to several mM [60] and short chain fatty acid analogs (such as
C8-PIP2) have even higher solubilities and micelle concentrations.
By direct addition of PIP2 to the capillaries, the full multidimen-
sional binding spectrum of Ca2+ and PIP2 could be determined with
a single set of MST experiments (Fig. 7C). In the presence of satu-
rating concentrations of PIP2 (>10 lM), the apparent binding affin-
ity for Ca2+ was increased more than 40-fold [56]. This interplay
between Ca2+, PIP2 and syt1 has profound implications for the
mechanisms of neurotransmitter release.
4.5. Competitive small molecule binding to histone methyltransferase
G9a
The histone methyltransferase (HMT) G9a plays a crucial role in
epigenetic regulation and has been implicated in cancer [61]. Thus,
G9a inhibitors are expected to exert synergistic effects in epige-
netic cancer therapy. A potent new G9a modulator is UNC0321,
[62] a BIX-01294 analog. The latter was originally identified as a
G9a inhibitor with an IC50 ranging from sub-lM (Thioglo assay
and AlphaScreen assay) [63] to low lM (DELFIA format) [64].
Through an antibody-based time-resolved fluorescence assay,
BIX-01294 was found to be the first non-peptidomimetic com-
pound that inhibited G9a in a non-competitive mode versus the
methyl donor, S-adenosyl-L-methionine (SAM) [64]. Furthermore,
it was confirmed by co-crystallization with G9a-like protein that
BIX-01294 acted as a competitive inhibitor for the peptide sub-
strate [65]. Despite the availability of several different assay for-
mats to measure HMT activity [66], direct or competition binding
assays for HMTs and their potential inhibitors have been largely
limited to FP, ITC or differential scanning fluorimetry (DSF) exper-
iments [63]. Thus, MST could provide further information on the
G9a system by assessing the direct interaction between the protein
and BIX-01294, the protein and its cognate substrate peptide, and
the mode of action of BIX-01294 versus both the peptide and the
cofactor.
We firstly evaluated the affinity of BIX-01294 for G9a via MST.
We obtained a KD of 0.7 ± 0.2 lM in both the label-free approach
and using NT495-labeled G9a (Fig. 8A), which demonstrates, that
the label did not have an influence on the binding. The values are
in the same general range established by the enzymatic IC50 values
for the compound (reported in multiple papers and summarized in
Liu et al. 2009 [63] to be between 1.7 and 1.9 lM) and the ITC-
derived KD of 0.13 lM (reported in Liu et al. 2009 [63]). This further
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validates both of our MST assays and showcases the ability of MST
to detect binding interactions between proteins (G9a; 32.6 kDa)
and small molecules (BIX-01294; 490.6 Da) in spite of the extreme
size ratio. We subsequently studied the binding of G9a, labeled
with either NT495 or NT647, to its cognate peptide substrate, a bio-
tinylated histone peptide (b-H3(1–21)). Both labeled G9a versions
yielded identical KDs, with the former giving a KD of 1.5 ± 0.4 lM
and the latter a KD of 1.5 ± 0.2 lM (Fig. 8B). These values are in
close agreement with the KMs reported for similar peptide sub-
strates against mammalian G9a [67]. Next, we investigated the
mode of inhibitory action of BIX-01294 with respect to either the
peptide substrate b-H3(1–21) or the SAM cofactor. Prior to BIX-
01294 titration, each component was pre-incubated with NT495-
G9a at either a concentration near its respective KD or at saturating
amounts. The results were compared to BIX-01294-G9a binding in
absence of the components. As expected, the apparent KD for BIX-
01294 against G9a was reduced upon increasing concentrations of
b-H3(1–21), suggesting that the compound was competing with
the peptide for binding to the histone binding site (Fig. 8C). In con-
trast, the addition of increasing concentrations of SAM had little
effect on the compound’s affinity for G9a (Fig. 8D), indicating that
the compound was not competing with SAM. These results are in
good agreement with previous enzyme kinetic [64] and co-crystal-
lization studies [65] aimed at elucidating the ligands’ mode of
action. In summary, the G9a case study demonstrates that MST
not only provides enough sensitivity to quantify protein-small
molecule interactions but also yields binding affinities that are
comparable with those obtained from well-established methods,
such as ITC. Moreover, MST has clearly been shown to be able to
offer insight on the mode of action of small molecules versus the
target protein’s native substrate or cofactor.
5. Conclusion
We successfully used MST to quantify the interaction of differ-
ent proteins with a variety of binding partners. In all cases, the
determined KDs were in agreement with results obtained by other,
well-established biophysical techniques for protein interaction
analysis. As MST is a capillary based format and binding-induced
changes in thermophoretic mobility are detected via fluorescence,
ll–volumes and low nM–concentrations are sufficient. This results
in small sample consumption and allows direct quantification of
high affinity protein dimerization as in the case of Grb2. The
measured KD of 0.7 lM lies well below the minimally usable,
lM-concentrations for ITC [8]. The monomeric state and mono-
mer–dimer-transition of Grb2 would not be captured and quantifi-
cation via ITC would not be possible.
The free solution approach of MST avoids immobilization proce-
dures and possible surface artifacts. Labeling artifacts can be
excluded entirely by using label-free MST, which only requires a
sufficient intrinsic UV-fluorescence of the protein binding partner.
In standard MST, the use of different fluorescent labels provides a
means of excluding labeling effects as demonstrated for G9a-bind-
ing to b-H3(1-21). Additionally, the fluorescent label can be at-
tached to either of the binding partners to test for possible label-
dependent changes of the binding behavior as shown in the
AMA1-RON2 experiment. This reversibility in assay design results
from the fact that thermophoresis is sensitive to various molecular
properties and thus, MST, in contrast to DLS, FP and SPR, does not
rely on size changes alone and is not limited by the molecular
weight ratio of the binding partners. The strongly preferred assay
design for SPR and FP, on the other hand, is to measure interactions
by titrating the larger binding partner to a constant amount of the
smaller one. However, labeling or immobilizing the smaller ligand
bears a higher risk of changing its properties, as the label or anchor
is large compared to the ligand. For MST, the reversed assay design
of measuring the binding of an unlabeled small molecule to a much
bigger, fluorescent protein works equally well, as illustrated by the
G9a-BIX-01294 interaction analysis and the label-free GPCR bind-
ing studies.
The solution, in which the MST experiment is performed, can be
chosen freely to meet the sample’s specific buffer requirements.
This is invaluable when working with membrane proteins like
GPCRs, which typically require strictly optimized buffer conditions
and detergents to be stabilized in solution. In addition to buffers
with all kinds of additives, proteins embedded in liposomes can
be analyzed via MST as well, as demonstrated by the syt1-mea-
surement. MST can also be performed in complex bioliquids such
as cell lysate. When combined with the use of fluorescent fusion
proteins, as illustrated in the TEM1-BLIP analysis, the fusion pro-
tein does not even have to be purified prior to the measurement,
but the crude cell extract can directly be used. For the TEM1-BLIP
system, the affinities in buffer and lysate were in good agreement.
Discrepancies can, however, appear between simple buffers and
complex fluids [17]. This demonstrates the importance of analyz-
ing protein interaction in its natural, crowded environment. Apart
from cell lysate, MST can also be performed in untreated human
blood serum, allowing direct quantification of affinity and concen-
tration of antibodies as disease related biomarkers [68].
In addition, complex binding modes are readily accessible via
MST, e.g. competition in the binding of BIX-01294 and b-H3(1-
21) to G9a. Furthermore, the cooperative binding of PIP2 and
Ca2+ to syt1 was quantified via MST. In previous assays, cooperativ-
ity had been inferred from Ca2+ binding to membranes. Thus, lipo-
somes with low PIP2 content were used, to which syt1 only binds
in presence of Ca2+. MST with soluble PIP2 allowed to measure un-
der saturating PIP2 conditions. As a result, PIP2 binding in absence
of Ca2+ was captured as well, revealing a much higher cooperativ-
ity. Due to the low solubility and micelle concentration of PIP2, it
would not be possible to perform a comparable assay with a tech-
nique requiring higher sample concentrations than MST.
MST provides reliable quantitative information on protein inter-
action based on a simple protocol, making measurements fast and
efficient with low sample consumption. It is sensitive to binding-
induced changes in several molecular properties and flexible in as-
say design. Taken together, this makes MST a highly applicable tool
for protein interaction analysis, even for challenging biological
systems.
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